Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in ...
Ramat Gan, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Risk stratification in compensated advanced chronic liver disease has traditionally been based on the identification of ...
Ramat Gan, Israel, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs ...
Developing improved care models for decompensated liver disease is one of the major clinical challenges in gastroenterology and hepatology, and in a recent landmark study, published in Hepatology, ...
Decompensated cirrhosis is defined as an acute deterioration in liver function in a patient with cirrhosis and is characterized by jaundice, ascites, hepatic encephalopathy, hepatorenal syndrome, or ...
Please provide your email address to receive an email when new articles are posted on . Patients who used statins had a reduced risk for HCC, hepatic decompensation and fibrosis progression.
When the body can no longer compensate the gradual failure of the liver caused by liver cirrhosis, there is a high risk of acute decompensated liver cirrhosis. In some patients this develops quickly ...
Please provide your email address to receive an email when new articles are posted on . Among patients with alcoholic-related liver disease in early stages, 15% progressed to decompensation and 22% ...
Chronic liver disease and even cirrhosis can go unnoticed for a long time because many patients have no symptoms: the liver suffers silently. When the body is no longer able to compensate for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results